Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer

Eddy S. Leman, Robert E. Schoen, Ahmed Magheli, Lori J Sokoll, Daniel Wan-Yui Chan, Robert H. Getzenberg

Research output: Contribution to journalArticle

Abstract

Purpose: A blood test to detect colon cancer at a preventable stage would represent a major advancement. We have previously identified colon cancer-specific markers using focused proteomics analysis of nuclear structural proteins. Two of these markers, colon cancer-specific antigen (CCSA)-3 and CCSA-4, have been developed into blood-based markers that are able to distinguish individuals with colorectal cancer from those without. CCSA-2 is a distinct novel colon cancer marker identified using focused proteomics. Experimental Design: Using an indirect ELISA on serum samples obtained from two institutions, we evaluated CCSA-2 as a serum-based colon cancer marker. A total of 111 serum samples from individuals who underwent colonoscopy and were subsequently diagnosed as either being normal or having hyperplastic polyps, nonadvanced adenomas, advanced adenomas, and colorectal cancer were evaluated. A diverse control population that consisted of 125 serum samples was also included in this study. Results: Receiver operating characteristic analyses were used to measure the sensitivity and specificity of CCSA-2. CCSA-2 at a cutoff of 10.8 μg/mL has overall specificity of 78.4% [95% confidence interval (95% CI), 67.3-87.1%] and sensitivity of 97.3% (95% CI, 85.8-99.5%) in separating individuals with advanced adenomas and colorectal cancer from normal, hyperplastic, and nonadvanced adenoma populations. The receiver operating characteristic curve for CCSA-2 has an area under the curve of 0.90 (95% CI, 0.83-0.95). Conclusion: Our initial study shows that CCSA-2 is a potential serum-based marker for colon cancer detection with high sensitivity and specificity.

Original languageEnglish (US)
Pages (from-to)1349-1354
Number of pages6
JournalClinical Cancer Research
Volume14
Issue number5
DOIs
StatePublished - Mar 1 2008

Fingerprint

Colonic Neoplasms
Colorectal Neoplasms
Biomarkers
Adenoma
Confidence Intervals
Serum
ROC Curve
colon-specific antigen
Proteomics
Sensitivity and Specificity
Hematologic Tests
Colonoscopy
Nuclear Proteins
Polyps
Population
Area Under Curve
Research Design
Enzyme-Linked Immunosorbent Assay

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer. / Leman, Eddy S.; Schoen, Robert E.; Magheli, Ahmed; Sokoll, Lori J; Chan, Daniel Wan-Yui; Getzenberg, Robert H.

In: Clinical Cancer Research, Vol. 14, No. 5, 01.03.2008, p. 1349-1354.

Research output: Contribution to journalArticle

Leman, Eddy S. ; Schoen, Robert E. ; Magheli, Ahmed ; Sokoll, Lori J ; Chan, Daniel Wan-Yui ; Getzenberg, Robert H. / Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 5. pp. 1349-1354.
@article{6835e3aff2a6448fb29bde8458347305,
title = "Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer",
abstract = "Purpose: A blood test to detect colon cancer at a preventable stage would represent a major advancement. We have previously identified colon cancer-specific markers using focused proteomics analysis of nuclear structural proteins. Two of these markers, colon cancer-specific antigen (CCSA)-3 and CCSA-4, have been developed into blood-based markers that are able to distinguish individuals with colorectal cancer from those without. CCSA-2 is a distinct novel colon cancer marker identified using focused proteomics. Experimental Design: Using an indirect ELISA on serum samples obtained from two institutions, we evaluated CCSA-2 as a serum-based colon cancer marker. A total of 111 serum samples from individuals who underwent colonoscopy and were subsequently diagnosed as either being normal or having hyperplastic polyps, nonadvanced adenomas, advanced adenomas, and colorectal cancer were evaluated. A diverse control population that consisted of 125 serum samples was also included in this study. Results: Receiver operating characteristic analyses were used to measure the sensitivity and specificity of CCSA-2. CCSA-2 at a cutoff of 10.8 μg/mL has overall specificity of 78.4{\%} [95{\%} confidence interval (95{\%} CI), 67.3-87.1{\%}] and sensitivity of 97.3{\%} (95{\%} CI, 85.8-99.5{\%}) in separating individuals with advanced adenomas and colorectal cancer from normal, hyperplastic, and nonadvanced adenoma populations. The receiver operating characteristic curve for CCSA-2 has an area under the curve of 0.90 (95{\%} CI, 0.83-0.95). Conclusion: Our initial study shows that CCSA-2 is a potential serum-based marker for colon cancer detection with high sensitivity and specificity.",
author = "Leman, {Eddy S.} and Schoen, {Robert E.} and Ahmed Magheli and Sokoll, {Lori J} and Chan, {Daniel Wan-Yui} and Getzenberg, {Robert H.}",
year = "2008",
month = "3",
day = "1",
doi = "10.1158/1078-0432.CCR-07-4110",
language = "English (US)",
volume = "14",
pages = "1349--1354",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer

AU - Leman, Eddy S.

AU - Schoen, Robert E.

AU - Magheli, Ahmed

AU - Sokoll, Lori J

AU - Chan, Daniel Wan-Yui

AU - Getzenberg, Robert H.

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Purpose: A blood test to detect colon cancer at a preventable stage would represent a major advancement. We have previously identified colon cancer-specific markers using focused proteomics analysis of nuclear structural proteins. Two of these markers, colon cancer-specific antigen (CCSA)-3 and CCSA-4, have been developed into blood-based markers that are able to distinguish individuals with colorectal cancer from those without. CCSA-2 is a distinct novel colon cancer marker identified using focused proteomics. Experimental Design: Using an indirect ELISA on serum samples obtained from two institutions, we evaluated CCSA-2 as a serum-based colon cancer marker. A total of 111 serum samples from individuals who underwent colonoscopy and were subsequently diagnosed as either being normal or having hyperplastic polyps, nonadvanced adenomas, advanced adenomas, and colorectal cancer were evaluated. A diverse control population that consisted of 125 serum samples was also included in this study. Results: Receiver operating characteristic analyses were used to measure the sensitivity and specificity of CCSA-2. CCSA-2 at a cutoff of 10.8 μg/mL has overall specificity of 78.4% [95% confidence interval (95% CI), 67.3-87.1%] and sensitivity of 97.3% (95% CI, 85.8-99.5%) in separating individuals with advanced adenomas and colorectal cancer from normal, hyperplastic, and nonadvanced adenoma populations. The receiver operating characteristic curve for CCSA-2 has an area under the curve of 0.90 (95% CI, 0.83-0.95). Conclusion: Our initial study shows that CCSA-2 is a potential serum-based marker for colon cancer detection with high sensitivity and specificity.

AB - Purpose: A blood test to detect colon cancer at a preventable stage would represent a major advancement. We have previously identified colon cancer-specific markers using focused proteomics analysis of nuclear structural proteins. Two of these markers, colon cancer-specific antigen (CCSA)-3 and CCSA-4, have been developed into blood-based markers that are able to distinguish individuals with colorectal cancer from those without. CCSA-2 is a distinct novel colon cancer marker identified using focused proteomics. Experimental Design: Using an indirect ELISA on serum samples obtained from two institutions, we evaluated CCSA-2 as a serum-based colon cancer marker. A total of 111 serum samples from individuals who underwent colonoscopy and were subsequently diagnosed as either being normal or having hyperplastic polyps, nonadvanced adenomas, advanced adenomas, and colorectal cancer were evaluated. A diverse control population that consisted of 125 serum samples was also included in this study. Results: Receiver operating characteristic analyses were used to measure the sensitivity and specificity of CCSA-2. CCSA-2 at a cutoff of 10.8 μg/mL has overall specificity of 78.4% [95% confidence interval (95% CI), 67.3-87.1%] and sensitivity of 97.3% (95% CI, 85.8-99.5%) in separating individuals with advanced adenomas and colorectal cancer from normal, hyperplastic, and nonadvanced adenoma populations. The receiver operating characteristic curve for CCSA-2 has an area under the curve of 0.90 (95% CI, 0.83-0.95). Conclusion: Our initial study shows that CCSA-2 is a potential serum-based marker for colon cancer detection with high sensitivity and specificity.

UR - http://www.scopus.com/inward/record.url?scp=40949154676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40949154676&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-4110

DO - 10.1158/1078-0432.CCR-07-4110

M3 - Article

C2 - 18316554

AN - SCOPUS:40949154676

VL - 14

SP - 1349

EP - 1354

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -